Drug Development Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X

Most Read

  1. New drugs and therapeutic options help the immune system fight cancer
  2. Roche’s Tecentriq threatens BMS’ Opdivo in small cell lung cancer market
  3. The challenges of using stem cells in neurology
  4. Another BACE inhibitor fails in phase III trials
  5. May’s top news stories

Latest Content

Quick and Flexible Elemental Screening with Omnian

Omnian was developed for Malvern Panalytical's high-end x-ray fluorescence (XRD) spectrometer and is also available for the Epsilon 4 energy dispersive x-ray fluorescence (EDXRF) benchtop systems. This powerful combination brings together the strengths of Omnian with the ease-of-use of Epsilon 4.

July’s top news stories

The Kyoto University’s Centre for iPS Cell Research and Application (CiRA) in Japan is to start two clinical trials that will evaluate human induced pluripotent stem cells (iPS) to treat Parkinson’s disease, and Critical Path Institute’s (C-Path) Critical Path for Parkinson’s Consortium (CPP), along with Parkinson’s UK, announced that the European Medicines Agency (EMA) issued a positive qualification opinion on biomarker as a tool to boost clinical trials on Parkinson’s. Drugdevelopment-technology.com wraps up the key news stories from July 2018.

Getting Acquainted with the Theory of XRF

This white paper provides a general introduction to X-ray Fluorescence (CRF) spectrometry and XRF analysis. It explains how a spectrometer works and how XRF analysis is achieved.

Pre-Clinical and Clinical Studies in Dermatology

Monasterium Laboratory's pre-clinical research philosophy is to operate as much as possible with intact human hair follicles and skin, which are then exposed to test agents ex vivo (organ culture) or in vivo (human skin xenotransplants on SCID mice).

June’s top news stories

Servier and Galapagos commenced the ROCCELLA Phase 2 clinical trial to evaluate the efficacy and safety of S201086/GLPG1972 to treat patients with knee osteoarthritis (OA); and Boehringer Ingelheim Pharmaceuticals and Eli Lilly and Company reported positive top-line results from the EASE trial programme. Drugdevelopment-technology.com wraps up the key news stories from June 2018.

Latest News

Read our magazine

Pharma Technology Focus is the essential reading material for decision-makers in the pharmaceutical industry, bringing you the latest news and analysis in an exciting, interactive format.

Send me notifications of new editions:

Go Top